

CLAIMS

1. Use of a first agent endowed with tumour tropism in combination with a second anticancer agent endowed with affinity for said first agent as active ingredients for the preparation of a medicament useful for the two-step perioperative therapy of solid tumours.
2. Use according to claim 1, in which said agent endowed with tumour tropism contains one or more antibodies specific for antigens associated with a tumour.
3. Use according to claim 2, in which the antibody or antibodies in said medicament are biotinylated and are in combination with an avidin compound and said second agent is a biotin compound bearing an anticancer agent.
4. Use according to claim 2, in which the antibody in said medicament is avidinated and is in combination with a biotin compound bearing an anticancer agent.
5. Use according to one of claims 2-4, in which said one or more antibodies are monoclonal, and optionally chimeric or recombinant.
6. Use according to one of claims 2-5, in which said antibody is antitenascin.
7. Use according to claim 2, in which said first agent is avidin and said second agent is a biotin compound bearing an anticancer agent.
8. Use according to any of the foregoing claims, in which said anticancer agent is selected from the group consisting of radioisotopes, chemotherapeutic agents, toxins and anticancer cells.

9. Use according to claim 8, in which said radioisotope is selected from the group consisting of Fe-52, Mn-52m, Co-55, Cu-64, Ga-67, Ga-68, Tc-99m, In-111, I-123, I-125, I-131, P-32, Sc-47, Cu-67, Y-90, Pd-109, Ag-111, I-131, Pm-149, Re-186, Re-188, At-211, Pb-212, Bi-212, and Lu-177.
10. Use according to claim 9, in which said radioisotope is Y-90 or Lu-177.
11. Use according to claim 3, in which the biotinylated antibody, the avidin compound and the biotin compound in said medicament are in separate containers.
12. Use according to claim 4, in which the avidinated antibody and the biotin compound in said medicament are in separate containers.
13. Use according to claim 7, in which the avidin and the biotin compound in said medicament are in separate containers.
14. Use according to one of the foregoing claims, in which said tumour is selected from the group consisting of breast, pancreas, lung, pleural, peritoneal, cervico-facial, brain and bladder tumours.
15. Use according to one of claims 3-13, in which said avidin is selected from the group consisting of avidin, streptavidin, their polymeric derivatives and their derivatives with polyethylene glycol..
16. Use according to one of the foregoing claims, in which said medicament is suitable for injectable administration.
17. Use according to claim 16, in which the container of said antibody is in the form of a syringe equipped with one or more needles.
18. Use according to one of claims 11-13, in which the container of said antibody is suitable for administration in the form of a spray.

19. Use according to claim 11, in which said antibody or mixture of antibodies is contained in a first separate container in a single dose.
20. Use according to claim 11, in which said avidin is contained in a second separate container in a single dose.
21. Use according to claim 3, in which the amount of avidin in said medicament is in a ratio of from 5:1 to 10:1 to the amount of antibody or mixture of antibodies.
22. Use according to claim 11, in which the container of said avidin is in the form of a syringe suitable for successive administrations of precise volumes.
23. Use according to claim 7, in which said avidin is contained in a separate container in a single dose.
24. Use according to claim 7, in which the container of said avidin is suitable for administration in the form of a spray..
25. Kit for two-step adjuvant intra- and perioperative locoregional and/or systemic therapy, containing a set of separate containers, in which the first container contains a biotinylated antibody specific for antigens associated with a tumour or a mixture of antibodies, the second container contains an avidin compound, the third container contains a biotin compound bearing an anticancer agent, and optionally a fourth container containing biotinylated albumin.
26. Kit for two-step adjuvant intra- and perioperative locoregional and/or systemic therapy, containing a set of separate containers, in which the first container contains an avidinated antibody specific for antigens associated with a tumour or a mixture of antibodies, and the second container contains a biotin compound bearing an anticancer agent.

27. Kit for two-step adjuvant intra- and perioperative locoregional and/or systemic therapy, containing a set of separate containers, in which the first container contains an avidin compound, and the second container contains a biotin compound bearing an anticancer agent.
28. Use of a first agent endowed with tumour tropism in combination with a second radiolabelled agent endowed with affinity for said first agent for the preparation of a diagnostic composition for the pretherapeutic biodistribution of the medicament according to claim 1.